Cargando…
A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response
Zoledronic acid is a bisphosphonate commonly used to treat various conditions involving bone loss. While it is generally well-tolerated, the occurrence of severe inflammatory reactions is rare. We present the case of an 82-year-old female who developed a severe immune reaction, including weakness an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404464/ https://www.ncbi.nlm.nih.gov/pubmed/37551226 http://dx.doi.org/10.7759/cureus.41524 |
_version_ | 1785085304974082048 |
---|---|
author | Jamil, Maria Daneshvar, Amir Nachawati, Dana El Sharu, Husam Meysami, Alireza |
author_facet | Jamil, Maria Daneshvar, Amir Nachawati, Dana El Sharu, Husam Meysami, Alireza |
author_sort | Jamil, Maria |
collection | PubMed |
description | Zoledronic acid is a bisphosphonate commonly used to treat various conditions involving bone loss. While it is generally well-tolerated, the occurrence of severe inflammatory reactions is rare. We present the case of an 82-year-old female who developed a severe immune reaction, including weakness and tenderness in her upper and lower extremities, following a single dose of zoledronic acid infusion for the treatment of osteoporosis. The onset of symptoms occurred one week after the infusion and persisted, progressively worsening over time, leading to functional impairment and the need for a walker for ambulation. Laboratory studies revealed an elevated erythrocyte sedimentation rate while other autoimmune markers were within normal limits. Differential diagnosis included an adverse reaction to zoledronic acid or underlying polymyalgia rheumatica. The patient showed significant improvement with a prednisone taper, suggesting an immune-mediated response. This case highlights the importance of considering severe immune reactions as a potential side effect of zoledronic acid and emphasizes the need for further research to better understand the underlying mechanisms and optimize patient management. |
format | Online Article Text |
id | pubmed-10404464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-104044642023-08-07 A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response Jamil, Maria Daneshvar, Amir Nachawati, Dana El Sharu, Husam Meysami, Alireza Cureus Endocrinology/Diabetes/Metabolism Zoledronic acid is a bisphosphonate commonly used to treat various conditions involving bone loss. While it is generally well-tolerated, the occurrence of severe inflammatory reactions is rare. We present the case of an 82-year-old female who developed a severe immune reaction, including weakness and tenderness in her upper and lower extremities, following a single dose of zoledronic acid infusion for the treatment of osteoporosis. The onset of symptoms occurred one week after the infusion and persisted, progressively worsening over time, leading to functional impairment and the need for a walker for ambulation. Laboratory studies revealed an elevated erythrocyte sedimentation rate while other autoimmune markers were within normal limits. Differential diagnosis included an adverse reaction to zoledronic acid or underlying polymyalgia rheumatica. The patient showed significant improvement with a prednisone taper, suggesting an immune-mediated response. This case highlights the importance of considering severe immune reactions as a potential side effect of zoledronic acid and emphasizes the need for further research to better understand the underlying mechanisms and optimize patient management. Cureus 2023-07-07 /pmc/articles/PMC10404464/ /pubmed/37551226 http://dx.doi.org/10.7759/cureus.41524 Text en Copyright © 2023, Jamil et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Endocrinology/Diabetes/Metabolism Jamil, Maria Daneshvar, Amir Nachawati, Dana El Sharu, Husam Meysami, Alireza A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response |
title | A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response |
title_full | A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response |
title_fullStr | A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response |
title_full_unstemmed | A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response |
title_short | A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response |
title_sort | rare presentation of zoledronate-induced systemic inflammatory response |
topic | Endocrinology/Diabetes/Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404464/ https://www.ncbi.nlm.nih.gov/pubmed/37551226 http://dx.doi.org/10.7759/cureus.41524 |
work_keys_str_mv | AT jamilmaria ararepresentationofzoledronateinducedsystemicinflammatoryresponse AT daneshvaramir ararepresentationofzoledronateinducedsystemicinflammatoryresponse AT nachawatidana ararepresentationofzoledronateinducedsystemicinflammatoryresponse AT elsharuhusam ararepresentationofzoledronateinducedsystemicinflammatoryresponse AT meysamialireza ararepresentationofzoledronateinducedsystemicinflammatoryresponse AT jamilmaria rarepresentationofzoledronateinducedsystemicinflammatoryresponse AT daneshvaramir rarepresentationofzoledronateinducedsystemicinflammatoryresponse AT nachawatidana rarepresentationofzoledronateinducedsystemicinflammatoryresponse AT elsharuhusam rarepresentationofzoledronateinducedsystemicinflammatoryresponse AT meysamialireza rarepresentationofzoledronateinducedsystemicinflammatoryresponse |